Q1 Earnings Forecast for XENE Issued By HC Wainwright

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a report issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will earn ($0.88) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $53.00 target price on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.90) EPS and Q4 2025 earnings at ($0.91) EPS.

XENE has been the subject of a number of other research reports. William Blair upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Wedbush cut their price objective on Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Raymond James restated an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price objective on shares of Xenon Pharmaceuticals in a research note on Friday, August 9th. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $57.45.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock opened at $41.75 on Friday. Xenon Pharmaceuticals has a 52-week low of $28.10 and a 52-week high of $50.99. The firm has a market capitalization of $3.18 billion, a PE ratio of -14.80 and a beta of 1.25. The stock has a fifty day simple moving average of $41.14 and a two-hundred day simple moving average of $40.35.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same period in the previous year, the business earned ($0.73) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Blue Trust Inc. lifted its stake in shares of Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 641 shares during the period. nVerses Capital LLC purchased a new stake in Xenon Pharmaceuticals in the third quarter valued at approximately $102,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 487 shares in the last quarter. Quarry LP lifted its position in Xenon Pharmaceuticals by 207.7% during the second quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 2,700 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new position in Xenon Pharmaceuticals during the first quarter valued at approximately $195,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.